| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Hypertension. 2002;39:513.)
© 2002 American Heart Association, Inc.
Scientific Contributions |
From the First Department of Internal Medicine (Y.H., Sh.S., K.Na., M.K., Sa.S., K.No., K.H., H.M., K.C.), Division of Physical Therapy, Institute of Health Sciences (C.G.), and the Department of Clinical Laboratory Medicine (T.O.), Faculty of Medicine, Hiroshima University, Japan.
Correspondence to Yukihito Higashi, MD, PhD, FAHA, Division of Hypertension and Cardiology, First Department of Internal Medicine, Faculty of Medicine, Hiroshima University, 1-2-3 Kasumi, Minami-ku, Hiroshima 734-8551, Japan. E-mail yhigashi{at}hiroshima-u.ac.jp
| Abstract |
|---|
|
|
|---|
Key Words: pheochromocytoma norepinephrine nitric oxide acetylcholine endothelial function hypertension, essential
| Introduction |
|---|
|
|
|---|
-adrenergic receptors, causing vasoconstriction and glycogenolysis. Several previous studies have shown that both NO and NE contribute to the pathogenesis, development, and maintenance of hypertension.1,2,4,5,10 However, there is little information concerning the interaction of NO and NE on endothelial function in humans. Patients with pheochromocytoma (pheo)-secreted NE are ideal models for determining how endothelium-dependent and -independent vasodilation is affected under the influence of excess vasoconstrictors. We hypothesized that endothelial function is impaired in patients with adrenal pheo secreting NE and that surgical resection of the tumor would improve endothelial function in these patients.
To determine the role of excess NE in endothelial function, we evaluated the endothelium-dependent vasodilation induced by ACh and the endothelium-independent vasodilation induced by isosorbide dinitrate (ISDN) before and after adrenalectomy in patients with adrenal pheo secreting NE as compared with normotensive subjects and essential hypertensive patients.
| Methods |
|---|
|
|
|---|
Essential Hypertensive Patients
Hypertension was defined as a systolic blood pressure
140 mm Hg and/or a diastolic blood pressure
90 mm Hg measured in a sitting position on at least 3 different occasions in the outpatient clinic of Hiroshima University Faculty of Medicine. Secondary hypertensive patients were excluded on the basis of a complete history and physical examination, radiologic and ultrasound examinations, and urinalysis. Plasma renin activity, aldosterone and NE concentrations, and serum creatinine, potassium, calcium, and free thyroxine concentrations were determined; 24-hour urinary excretion of catecholamines, 17-hydroxycorticosteroids, 17-ketogenic steroids, and vanillylmandelic acid was measured as well. None of the patients had a history of antihypertensive treatment before the study.
Adrenal Pheo Patients
A diagnosis of pheo secreting NE was confirmed by biologic and pharmacologic tests, including the measurement of plasma NE (>2 ng/mL) and 24-hour urinary excretion of NE (>500 µg/d) and vanillylmandelic acid (>15 mg/d). Location of the tumor was identified by computed tomography, magnetic resonance imaging, and scintigraphy using an analogue of guanethidine labeled with 131I-metaiodobenzylguanidine. Only patients with a single adrenal tumor (right side: n=3; left side: n=5) were included. No patient had multiple endocrine neoplasias. No antihypertensive agents were taken by these patients for >2 weeks before the study.
Normotensive Subjects
Normal blood pressure was defined as a systolic blood pressure <140 mm Hg and a diastolic blood pressure <90 mm Hg. The normotensive control subjects had no history of serious diseases. No patients, including essential hypertensive and pheo patients, were currently smoking or had a history of smoking.
Forearm vascular responses to ACh (Daiichi Pharmaceutical Co) and ISDN (Eisai Pharmaceutical Co) were evaluated in all subjects. The study began at 8:30 AM. Subjects fasted the previous night for at least 12 hours. They were kept in the supine position in a quiet, dark, air-conditioned room (temperature 22°C to 25°C) throughout the study. A 23-gauge polyethylene catheter (Hakkow Co) was inserted into the left brachial artery for the infusion of ACh and ISDN and for the recording of arterial pressure with an AP-641G pressure transducer (Nihon Kohden Co) under local anesthesia (1% lidocaine). Another catheter was inserted into the left deep antecubital vein to obtain blood samples. After the patients were in the supine position for 30 minutes, we measured forearm blood flow (FBF) and arterial blood pressure. Then, the effects of the ACh and ISDN on forearm hemodynamics were measured. ACh (7.5, 15, and 30 µg/min) and ISDN (0.75, 1.5, and 3.0 µg/min) were infused intra-arterially for 5 minutes at each dose using a constant rate infusion pump (Terfusion STG-523, Termo Co). The FBF was measured during the last 2 minutes of the infusion. The infusions of ACh and ISDN were performed in a random order. Each study proceeded after the FBF had returned to baseline. Baseline fasting serum concentrations of total cholesterol, high-density lipoprotein (HDL) cholesterol, low-density lipoprotein (LDL) cholesterol, triglycerides, creatinine, insulin, glucose, electrolytes, and plasma nitrite/nitrate (NOx) and NE concentrations were obtained after the 30-minute rest period.
Study Protocol 2: Effect of Adrenalectomy on Endothelial Function in Patients With Pheo
Vasodilatory responses to ACh and ISDN were evaluated in a manner identical to study protocol 1 before adrenalectomy and within 4 weeks after this procedure in 8 patients with pheo. We confirmed that plasma and urinary NE concentrations and blood pressures were in the normal range after 2 weeks of surgery in all subjects. Surgical approaches to adrenalectomy included the open transabdominal approach in 3 of the patients and laparoscopic adrenalectomy in the remaining 5.
Measurement of FBF
The FBF was measured using a mercury-filled Silastic strain-gauge plethysmograph (EC-5R, D.E. Hokanson, Inc) as previously described.7,9 FBF was expressed as milliliters per minute per 100 mL of forearm tissue volume. Four plethysmographic measurements were averaged for analysis of FBF at baseline and during administration of drugs. Forearm vascular resistance (FVR) was calculated as the mean arterial pressure divided by FBF.
Analytical Methods
Routine chemical methods were used to determine serum concentrations of total cholesterol, HDL cholesterol, LDL cholesterol, triglycerides, creatinine, glucose, and electrolytes. Plasma concentrations of NOx were assayed by colorimetric methods using NOx assay kits (Cayman Chemical Co). The plasma and urinary concentrations of NE were measured by high-performance liquid chromatography.
Statistical Analysis
Results are presented as the mean±SD. Values of P<0.05 were considered significant. Multigroup comparisons of variables was performed by the 1-way ANOVA followed by the Bonferroni correction. Comparisons of parameters before and after adrenalectomy were performed with adjusted means by analysis of covariance using baseline data as covariates. Comparisons of time-course curves of parameters during the infusions of ACh and ISDN were analyzed by 2-way ANOVA for repeated measures on one factor followed by the Bonferroni correction for multiple-paired comparisons. When an interactive effect of drug reached statistical significance, the nature of this interaction was further investigated by applying 2-way ANOVA for repeated measured to 3 groups (normotensive, essential hypertensive, and pheo) without consideration of the factorial design. Relationships between variables were determined by linear regression analysis. The data were processed using the software packages StatView IV (SAS Institute Inc.) or Super ANOVA (Abacus Concepts).
| Results |
|---|
|
|
|---|
|
The intra-arterial infusion of ACh significantly increased FBF in a dose-dependent manner in all 3 groups. The response of FBF to ACh was greatest in normotensive subjects and least in patients with pheo (pheo versus essential hypertension, pheo versus normotension, and essential hypertension versus normotension, P<0.0001 for all; Figure 1, top). The intra-arterial infusion of ISDN significantly increased FBF in a dose-dependent manner in all 3 groups. The FBF response to ISDN was significantly smaller in patients with pheo than in the other groups (P<0.001 for all), although the vasodilatory effect of ISDN was similar in the normotensive subjects and essential hypertensive patients (Figure 1, bottom). The ratio of maximal ACh-stimulated FBF to maximal ISDN-stimulated FBF was greatest in normotensive subjects and least in patients with pheo (pheo versus essential hypertension, 1.1±0.1 versus 1.6±0.2; pheo versus normotension, 1.1±0.1 versus 2.4±0.4; and essential hypertension versus normotension, 1.6±0.2 versus 2.4±0.4; P<0.01 for all). No significant change was observed in the arterial blood pressure or heart rate with the intra-arterial infusion of either ACh or ISDN in any group.
|
Study Protocol 2: Effects of Adrenalectomy on Endothelial Function in Patients With Pheo
The baseline clinical characteristics before and after adrenalectomy of the 8 patients with pheo are summarized in the Table. Adrenalectomy significantly decreased serum glucose, plasma, and urinary NE, systolic and diastolic blood pressures, heart rate, and FVR and significantly increased serum insulin.
After adrenalectomy, FBF responses to both ACh and ISDN were enhanced in all patients (maximal FBF: 12.1±2.5 versus 32.2±9.6 mL/min per 100 mL tissue and 11.4±2.1 versus 15.4±3.6 mL/min per 100 mL tissue; P<0.05, respectively; Figure 2). No significant change was observed in the arterial blood pressure or heart rate in response to intra-arterial infusion of either ACh or ISDN before and after adrenalectomy. The ratio of maximal ACh-stimulated FBF to maximal ISDN-stimulated FBF was significantly higher after adrenalectomy than before adrenalectomy (2.1±0.4 versus 1.1±0.1; P<0.05). The increase in maximal FBF response to ACh correlated significantly with the decrease in urinary excretion of NE (r=-0.62, P<0.01; Figure 3) and the decrease in plasma concentrations of NE (r=-0.57, P<0.01). No significant correlation was seen between the increase in maximal FBF response to ACh and changes in blood pressure or variables, such as lipid, glucose, and insulin concentrations, or between these variables and the increase in maximal FBF response to ISDN.
|
|
| Discussion |
|---|
|
|
|---|
The forearm vascular response to ACh but not to ISDN was impaired in patients with essential hypertension. These findings are consistent with previous studies that demonstrated that endothelium-dependent vasodilation of brachial, coronary, renal, and small arteries is selectively impaired in patients with essential hypertension compared with normotensive subjects.69,1113 Patients with adrenal pheo secreting NE are an ideal model for the study of how endothelial function is altered in the presence of the excess vasoconstricting factors. In the present study, basal NO levels were similar in patients with pheo and the other groups. In contrast, stimulation with ACh blunted the endothelium-dependent vasodilation probably through a decrease in NO release in pheo patients. In addition, ISDN-induced vasodilation via smooth muscle cells was attenuated in these patients, although to a lesser degree than the endothelium-dependent vasodilatory response. Both ACh- and ISDN-stimulated vasodilation were blunted in patients with adrenal pheo secreting NE compared with patients with essential hypertension and normotensive subjects, indicating that both endothelial and smooth muscle function is impaired and may be restored after surgery in patients with pheo.
Several investigators have shown the existence of an interaction between NO and NE in intact endothelium.14,15 Greenberg et al16 reported that cyclic guanosine monophosphate (cGMP) may be a prejunctional regulator of NE as a sympathetic neurotransmitter in the vasculature. These findings suggest that both NO and cGMP may act as endogenous inhibitors of NE release in vascular smooth muscle. However, this compensatory mechanism of NE release may not naturally function under excess levels of NE. In the present study, the improvement of endothelium-dependent vasodilation significantly correlated with the decrease in NE concentrations. One possible mechanism by which surgical resection of NE-secreting tumors augments endothelium-dependent vasodilation is a decrease in NE release. An imbalance between NO and NE may directly result in conditions associated with the endothelial dysfunction in humans.
It is widely known that diseases of abnormal glucose metabolism, such as diabetes mellitus, are associated with endothelial dysfunction.17,18 In pheo patients, increases in serum glucose and decreases in insulin were caused by excess NE. Although serum glucose and insulin concentrations returned to levels similar to normotensive subjects after surgical resection of the adrenal tumor, there was no significant correlation between the improvement in endothelial function and changes in serum glucose and insulin. In addition, abnormal lipid metabolism, such as what occurs with hypercholesterolemia, is associated with endothelial dysfunction.19,20 In the present study, the concentrations of total and LDL cholesterol were higher, although not significantly, in patients with pheo compared with the other groups. There was no correlation between the improvement in endothelial function and changes in the lipid profile, suggesting that modification of the lipid profile does not contribute to the adrenalectomy-induced restoration of endothelial function.
Endothelial function becomes impaired as blood pressure increases, and the degree of dysfunction is related to the severity of the hypertension.21,22 It is expected that endothelial dysfunction is improved by antihypertensive therapy. However, several experimental and clinical studies have found conflicting results concerning the relationship between the reduction in blood pressure and the improvement in endothelial function.23 Although in the present study, adrenalectomy acutely decreased blood pressure in patients with pheo, changes in blood pressure did not correlate with the improvement of FBF response to either ACh or ISDN. In previous studies, we and other investigators showed that although clinically effective antihypertensive therapy, such as angiotensin converting enzyme inhibitors and aerobic exercise, have restored resistance artery endothelial function of forearm circulation in patients with essential hypertension, there is no significant correlation between the degree of reduction in blood pressure and the augmentation of endothelium-dependent vasodilation.2427 Therefore, a reduction in blood pressure per se may not be involved in the restoration of resistance artery endothelial function in the forearm circulation.
Although relatively rare, impairment of smooth muscle response to NO may occur in patients with pheo in contrast to previous observations that such endothelium-independent vasodilation is not impaired in atherosclerosis, coronary heart disease, hypertension (including essential hypertension, primary aldosteronism, and renovascular hypertension), and even heart failure. Instead of vascular smooth muscle function, endothelium-dependent vasodilation has been shown to be impaired in these other conditions.69,28,29 This may be explained by the fact that circulating NE mainly stimulates
-adrenergic receptors, located on vascular smooth muscle, causing vasoconstriction and thereby elevating blood pressure in patients with pheo. The excess circulating NE may contribute, at least in part, to the blunted smooth muscle response to exogenous NO. However, because there was no significant correlation between the improvement of ISDN-stimulated vasodilation and the decrease in NE concentrations after adrenalectomy, it is unlikely that the removal of excess NE directly restores endothelium-independent vasodilation after adrenalectomy.
Conversely, our results suggest that adrenalectomy-induced structural alterations may occur in patients with pheo. Interestingly, ISDN-stimulated vasodilation was quickly restored after adrenalectomy. We confirmed this restoration within 2 weeks after adrenalectomy in 5 of the 8 patients with laparoscopic adrenalectomy. Although we cannot deny the possibility that vascular structural adjustments after adrenalectomy contribute to the normalization of vascular response to ISDN, it is unlikely that structural changes, including vascular smooth muscle cell proliferation and remodeling, occur in such a short period.
Study Limitations
In the present study, the number of patients with pheo was relatively small. Nonetheless, we observed a marked augmentation of endothelium-dependent vasodilation after adrenalectomy in patients with pheo.
The use of
(ß)-adrenergic receptor blockers would allow more specific conclusions concerning the effects of NE on endothelium-dependent and -independent vasodilation in the forearm circulation.
It is widely known that various vasoconstricting factors other than NE affect endothelium-dependent and -independent vasodilation in humans. We confirmed that circulating levels of endothelin-1 and angiotensin II were normal and were not changed after adrenalectomy (1.9±0.2 to 1.8±0.3 pg/mL and 14.2±6.9 to 15.3±7.1 pg/mL) in patients with pheo. However, we cannot deny the possibility that other vasoconstrictors contribute to impaired ACh- and ISDN-stimulated vasodilation and were restored after adrenalectomy in patients with pheo.
| Conclusions |
|---|
|
|
|---|
| Acknowledgments |
|---|
Received September 22, 2001; accepted November 12, 2001.
| References |
|---|
|
|
|---|
2. Vanhoutte PM. Endothelium and control of vascular function. Hypertension. 1989; 13: 658667.
3. Davies PF, Mundel T, Barbee KA. A mechanism for heterogeneous endothelial responses to flow in vivo and in vitro. J Biochem. 1995; 28: 15531560.
4. Furchgott RF. Role of endothelium in responses of vascular smooth muscle. Circ Res. 1983; 53: 557573.
5. Ress DD, Palmer RMJ, Moncada S. Role of endothelium-derived nitric oxide in the regulation of blood pressure. Proc Natl Acad Sci U S A. 1989; 86: 33753378.
6. Linder L, Kiowski W, Buhler FR, Lüscher TF. Indirect evidence for release of endothelium-derived relaxing factor in human forearm circulation in vivo: blunted response in essential hypertension. Circulation. 1990; 81: 17621767.
7. Panza JA, Quyyumi AA, Brush JE Jr, Epstein SE. Abnormal endothelium-dependent vascular relaxation in patients with essential hypertension. N Engl J Med. 1990; 323: 2227.[Abstract]
8. Taddei S, Agostino V, Mattei P, Ghiadoni L, Gennari A, Fasolo CB, Sudano I, Salvetti A. Aging and endothelial function in normotensive subjects and patients with essential hypertension. Circulation. 1995; 91: 19811987.
9. Higashi Y, Sasaki S, Kurisu S, Yoshimizu A, Sasaki N, Matsuura H, Kajiyama G, Oshima T. Regular aerobic exercise augments endothelium-dependent vascular relaxation in normotensive as well as hypertensive subjects: role of endothelium-derived nitric oxide. Circulation. 1999; 100: 11941202.
10. Goldstein DS. Plasma catecholamines in essential hypertension: an analytical review. Hypertension. 1983; 5: 8699.
11. Egashira K, Suzuki S, Hirooka Y, Kai H, Sugimachi M, Imaizumi T, Takeshita A. Impaired endothelium-dependent vasodilation in large epicardial and resistance coronary arteries in patients with essential hypertension: different responses to acetylcholine and substance P. Hypertension. 1995; 25: 201206.
12. Higashi Y, Oshima T, Ozono R, Matsuura H, Kajiyama G. Aging and severity of hypertension attenuate endothelium-dependent renal vascular relaxation in humans. Hypertension. 1997; 30: 252258.
13. Schiffrin EL, Park JB, Intengan HD, Touyz RM. Correction of arterial structure and endothelial dysfunction in human essential hypertension by the angiotensin receptor antagonist losartan. Circulation. 2000; 101: 16531659.
14. Ohyanagi M, Nishigaki K, Faber JE. Interaction between microvascular alpha 1- and alpha 2-adrenoceptors and endothelium-derived relaxing factor. Circ Res. 1992; 71: 188200.
15. Addicks K, Bloch W, Feelisch M. Nitric oxide modulates sympathetic neurotransmission at the prejunctional level. Microsc Res Tech. 1994; 29: 161168.[CrossRef][Medline] [Order article via Infotrieve]
16. Greenberg SS, Diecke FPJ, Peevy K, Tanaka TP. Release of norepinephrine from adrenergic nerve endings of blood vessels is modulated by endothelium-derived relaxing factor. Am J Hypertens. 1990; 3: 211218.[Medline] [Order article via Infotrieve]
17. Nitenberg A, Valensi P, Sachs R, Dali M, Aptecar E, Attali JR. Impairment of coronary vascular reserve and Ach-induced coronary arteries and normal left ventricular function. Diabetes. 1993; 43: 10171025.
18. Williams SB, Cusco JA, Roddy MA, Johnstone MT, Creager MA. Impaired nitric oxide-mediated vasodilation in patients with non-insulin-dependent diabetes mellitus. J Am Coll Cardiol. 1996; 27: 567574.[Abstract]
19. Drexler H, Zeiher AM, Meinzer K, Just H. Correction of endothelial dysfunction in coronary microcirculation of hypercholesterolaemic patients by L-arginine. Lancet. 1991; 338: 15461550.[CrossRef][Medline] [Order article via Infotrieve]
20. Casino PR, Kilcoyne CM, Quyyumi AA, Hoeg JM, Panza JA. The role of nitric oxide in endothelium-dependent vasodilation of hypercholesterolemic patients. Circulation. 1993; 88: 25412547.
21. Dohi Y, Thiel MA, Buhler FR, Lüscher TF. Activation of endothelial L-arginine pathway in resistance arteries. Effect of age and hypertension. Hypertension. 1990; 16: 170179.
22. Panza JA, Casino PR, Kilcoyne CM, Quyyumi AA. Role of endothelium-derived nitric oxide in the abnormal endothelium-dependent vascular relaxation of patients with essential hypertension. Circulation. 1993; 87: 14681474.
23. Creager MA, Roddy MA. Effect of captopril and enalapril on endothelial function in hypertensive patients. Hypertension. 1994; 24: 499505.
24. Higashi Y, Sasaki S, Nakagawa K, Ueda T, Yoshimizu A, Kurisu S, Matsuura H, Kajiyama G, Oshima T. A comparison of angiotensin-converting enzyme inhibitors, calcium antagonists, beta blockers and diuretic agents on reactive hyperemia in patients with essential hypertension: a multicenter study. J Am Coll Cardiol. 2000; 35: 284291.
25. Higashi Y, Sasaki S, Nakagawa K, Matsuura H, Kajiyama G, Oshima T. Effect of angiotensin-converting enzyme inhibitor imidapril on reactive hyperemia in patients with essential hypertension: relationship between treatment periods and resistance artery endothelial function. J Am Coll Cardiol. 2001; 37: 363370.
26. Schiffrin EL, Deng LY. Comparison of effects of angiotensin I-converting enzyme inhibition and ß-blockade for 2 years on function of small arteries from hypertensive patients. Hypertension. 1995; 25: 699703.
27. Iwatubo H, Nagano M, Sakai T, Kumamoto K, Morita R, Higaki J, Ogihara T. Converting enzyme inhibitor improves forearm reactive hyperemia in essential hypertension. Hypertension. 1997; 29: 286290.
28. Taddei S, Virdis A, Mattei P, Salvetti A. Vasodilation to acetylcholine in primary and secondary forms of human hypertension. Hypertension. 1993; 21: 929933.
29. Drexler H, Hayoz D, Munzel T, Horning T, Just H, Brunner HR, Zelis R. Endothelial function in chronic congestive heart failure. Am J Cardiol. 1992; 69: 15961601.[CrossRef][Medline] [Order article via Infotrieve]
This article has been cited by other articles:
![]() |
Z. Ungvari, A. Csiszar, P. M. Kaminski, M. S. Wolin, and A. Koller Chronic High Pressure-Induced Arterial Oxidative Stress: Involvement of Protein Kinase C-Dependent NAD(P)H Oxidase and Local Renin-Angiotensin System Am. J. Pathol., July 1, 2004; 165(1): 219 - 226. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Hypertension Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2002 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |